First Trust Advisors LP Has $2.22 Million Stock Position in Prestige Consumer Healthcare Inc. $PBH

First Trust Advisors LP increased its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 137.5% during the first quarter, HoldingsChannel reports. The firm owned 37,395 shares of the company’s stock after acquiring an additional 21,649 shares during the period. First Trust Advisors LP’s holdings in Prestige Consumer Healthcare were worth $2,216,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. AQR Capital Management LLC lifted its position in shares of Prestige Consumer Healthcare by 11.9% in the 1st quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock valued at $2,558,000 after acquiring an additional 3,200 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Prestige Consumer Healthcare by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock worth $2,535,000 after purchasing an additional 1,289 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Prestige Consumer Healthcare by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock valued at $46,997,000 after purchasing an additional 120,965 shares during the period. Jane Street Group LLC lifted its holdings in shares of Prestige Consumer Healthcare by 204.0% in the first quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock valued at $9,010,000 after purchasing an additional 70,330 shares in the last quarter. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after purchasing an additional 269 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on PBH shares. Canaccord Genuity Group lowered their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Zacks Research downgraded Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $70.75.

Prestige Consumer Healthcare Trading Up 0.9%

Shares of NYSE:PBH opened at $54.92 on Friday. The firm has a fifty day moving average of $48.82 and a two-hundred day moving average of $56.06. The firm has a market capitalization of $2.60 billion, a P/E ratio of 15.38, a price-to-earnings-growth ratio of 1.69 and a beta of 0.34. Prestige Consumer Healthcare Inc. has a 12-month low of $42.62 and a 12-month high of $71.07. The company has a quick ratio of 2.25, a current ratio of 3.23 and a debt-to-equity ratio of 1.06.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.09. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The business had revenue of $265.71 million for the quarter, compared to the consensus estimate of $250.34 million. During the same period in the prior year, the business posted $0.90 earnings per share. Prestige Consumer Healthcare’s revenue for the quarter was up 6.5% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. On average, equities analysts expect that Prestige Consumer Healthcare Inc. will post 4.6 EPS for the current fiscal year.

Trending Headlines about Prestige Consumer Healthcare

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Adjusted EPS was $0.98, exceeding the $0.89 analyst consensus and rising from $0.95 a year earlier. Revenue increased 6.5% year over year to $265.7 million, above the $250.3 million consensus estimate. Prestige Consumer Healthcare Q1 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Organic sales grew 3.2%, led by the gastrointestinal and dermatological categories, suggesting underlying demand remained resilient despite a challenging consumer environment.
• Positive Sentiment: Prestige raised fiscal 2027 guidance to revenue of $1.290 billion-$1.315 billion, adjusted EPS of $4.55-$4.65, and adjusted free cash flow of at least $270 million. The revenue outlook includes the recently acquired Breathe Right portfolio and LaCorium Health. Prestige Consumer Healthcare Fiscal 2027 First Quarter Results
• Positive Sentiment: Adjusted free cash flow rose to $83.7 million, and management said the cash generation should support deleveraging. The company also extended $400 million of debt maturities to 2034, moving its closest maturity to 2031.
• Neutral Sentiment: An analyst roundup cited a $70.75 price target, indicating potential upside relative to recent trading levels, though price targets reflect individual estimates rather than company guidance. Analysts Set Prestige Consumer Healthcare Price Target
• Negative Sentiment: GAAP diluted EPS fell to $0.61 from $0.95, while net income declined to $29.2 million from $47.5 million. Gross margin also contracted to 51.3% from 56.2%, and acquisition-related expenses and higher interest costs weighed on reported profitability.
• Negative Sentiment: Prestige ended the quarter with approximately $2 billion of net debt, increasing financial leverage and execution risk as it integrates the new acquisitions.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).